市場調査レポート

商品コード

1722823

がん/腫瘍プロファイリング市場レポート、規模、シェア、動向、予測：がんタイプ、技術、技法、用途、地域別、2025年～2033年

Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033

出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 136 Pages
納期: 2～3営業日

カスタマイズ可能

価格

PDF & Excel (Single User License)

USD 2,999 438,093円

レポートPDFおよびExcelを1名のみがご利用頂けるライセンスです。PDFおよびExcelの印刷は一度のみ可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (5 User License)

USD 3,999 584,173円

レポートPDFおよびExcelを同一企業内の5名様までがご利用頂けるライセンスです。PDFおよびExcelの印刷は可能です。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

PDF & Excel (Corporate License)

USD 4,999 730,253円

レポートPDFおよびExcelを企業内すべての方に使用頂けるライセンスです。PDFおよびExcel内のテキスト等の編集は可能ですが、事前にIMARC Services Private Limited社の許可が必要です。PDFおよびExcelの印刷回数に制限はありません。印刷したもののご利用はPDFおよびExcelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.08円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

がん/腫瘍プロファイリングの世界市場規模は2024年に124億7,000万米ドルとなりました。今後、IMARC Groupは、同市場が2033年までに262億9,000万米ドルに達し、2025～2033年のCAGRは8.21%になると予測しています。現在、北米が市場を独占しており、2024年には42.8%を超える大きな市場シェアを占めています。同市場は、精密医療の進歩、がん罹患率の上昇、個別化治療アプローチの採用増加などを背景に大きく成長しています。バイオマーカーに基づく診断に対する需要の高まりと、ゲノムおよびプロテオミクスプロファイリングにおける技術革新が相まって、市場はさらに拡大しています。

がん/腫瘍プロファイリング市場は、正確な分子診断を可能にするゲノムおよびプロテオミクス技術の進歩によって牽引されます。世界のがん罹患率の増加と個別化医療に対する需要の高まりががん/腫瘍プロファイリング市場の成長を加速させています。例えば、2024年12月、アスターDMヘルスケアは、Aster Cancer Conclaveにおいて、Precision Oncology Clinics、Aster Cancer Grid、Onco Collectの3つのイニシアチブの立ち上げを発表しました。これらのプログラムは、ゲノミックアプローチを通じて個別化されたデータ主導のがん治療を強化し、共同研究を促進し、インドを革新的ながん治療のリーダーとして位置づけ、患者の転帰を改善することを目的としています。腫瘍学研究における政府資金と民間投資も極めて重要な役割を果たしています。次世代シーケンシング（NGS）とバイオマーカー探索は早期発見と標的治療のためにますます採用されつつあり、リキッドバイオプシーの技術革新はプロファイリングの精度を向上させ、市場拡大を促進します。

米国がん/腫瘍プロファイリング市場は、がんの高い有病率と個別化医療に対する需要の高まりによって牽引されています。米国国立医学図書館が発表したデータによると、2024年には米国で新たに200万1,140人のがん患者が発生し、61万1,720人が死亡すると予測されています。次世代シーケンシング（NGS）などのゲノムおよびプロテオミクス技術の進歩により、腫瘍プロファイリングの精度が向上しています。腫瘍学研究に対する多額の政府資金と投資が市場の成長をさらに後押ししています。

がん/腫瘍プロファイリング市場動向：

がんの有病率の上昇

世界におけるがんの有病率の増加は、市場の成長を大きく後押ししています。がん罹患率はピークに達しており、患者の予後改善に向けて正確かつ特異的な診断ソリューションへの注目がますます高まる中、腫瘍プロファイリングのための高度な手法の必要性は年々高まり続けています。米国がん協会は、2022年には世界中で2,000万人近いがんの症例が診断され、970万人がこの病気が原因で死亡すると報告しています。この懸念すべき動向は、より良い診断と治療の選択肢に対する緊急の必要性を浮き彫りにしています。さらに、人口の高齢化、ライフスタイルの変化、環境への影響などの要因によって、がん患者数は2050年までに3,500万人に増加すると予測されています。これらの統計は、腫瘍プロファイリングが、がん治療におけるテーラーメイド治療と生存率向上のニーズに応える上で、ますます極めて重要な役割を果たすことを指摘しています。

ゲノミクスと精密医療の進歩

NGSやプロテオミクスを含むゲノム技術の進歩は、がん研究や治療プロセスに革命をもたらしました。腫瘍プロファイリング市場が急成長を遂げたのはこのためです。このような先端技術により、包括的な腫瘍プロファイリングが達成され、個々の患者の遺伝子構成に基づいた個別化治療の開発につながります。治療成績は向上しており、がん患者に的確な治療を提供することが重視されています。報告によると、がん医療への世界の投資額は2022年に約1,960億米ドルに達し、過去5年間の平均成長率は約12％でした。革新的な診断と治療アプリケーションへの要求が高まるにつれ、腫瘍のプロファイリングに高度なゲノム技術の利用が増加しています。このような開発は、腫瘍学の展望を変え、より効果的で的を絞ったがん治療への道を開くことで、前向きな市場展望を生み出しています。

政府と研究への資金提供

がんと精密医療への投資と資金は大きく伸びており、腫瘍プロファイリングを後押ししています。政府、製薬企業、その他の研究機関は、より高度なプロファイリングソリューションの開発に共同で取り組み、がんの早期診断と治療法の進歩を加速させています。Cancer Research UKの報告によると、英国政府は2027年までに研究開発（R&D）への投資総額をGDPの2.4%に増やすことを約束しています。このようなプログラムは、がん診断と治療における技術革新への注目が高まっていることを強調するものであり、これががん/腫瘍プロファイリング市場の需要を牽引しています。このような投資は、精密医療をより身近なものにするだけでなく、がんの個別化治療における画期的な技術革新を促進し、市場の成長を後押しします。

北米
- 米国
- カナダ
アジア太平洋地域
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
ラテンアメリカ
- ブラジル
- メキシコ
- その他
中東・アフリカ
- 市場内訳：国別

第11章 SWOT分析

概要
強み
弱み
機会
脅威

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

概要
買い手の交渉力
供給企業の交渉力
競合の程度
新規参入業者の脅威
代替品の脅威

第14章価格分析

第15章競合情勢

市場構造
主要企業
主要企業のプロファイル
- Abbott Laboratories
- Becton Dickinson and Company
- Caris Life Sciences
- Exact Sciences Corporation
- F. Hoffmann-La Roche Ltd
- Hologic Inc.
- HTG Molecular Diagnostics Inc.
- Illumina Inc.
- Laboratory Corporation of America Holdings
- NeoGenomics Laboratories
- Qiagen N.V.
- Siemens AG
- Sysmex Corporation

図表

List of Figures

Figure 1: Global: Cancer/Tumor Profiling Market: Major Drivers and Challenges
Figure 2: Global: Cancer/Tumor Profiling Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Cancer/Tumor Profiling Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Cancer/Tumor Profiling Market: Breakup by Cancer Type (in %), 2024
Figure 5: Global: Cancer/Tumor Profiling Market: Breakup by Technology (in %), 2024
Figure 6: Global: Cancer/Tumor Profiling Market: Breakup by Technique (in %), 2024
Figure 7: Global: Cancer/Tumor Profiling Market: Breakup by Application (in %), 2024
Figure 8: Global: Cancer/Tumor Profiling Market: Breakup by Region (in %), 2024
Figure 9: Global: Cancer/Tumor Profiling (Breast Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 10: Global: Cancer/Tumor Profiling (Breast Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 11: Global: Cancer/Tumor Profiling (Lung Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 12: Global: Cancer/Tumor Profiling (Lung Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 13: Global: Cancer/Tumor Profiling (Colorectal Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 14: Global: Cancer/Tumor Profiling (Colorectal Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 15: Global: Cancer/Tumor Profiling (Prostate Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 16: Global: Cancer/Tumor Profiling (Prostate Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 17: Global: Cancer/Tumor Profiling (Melanoma Cancer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 18: Global: Cancer/Tumor Profiling (Melanoma Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 19: Global: Cancer/Tumor Profiling (Other Cancer Types) Market: Sales Value (in Million USD), 2019 & 2024
Figure 20: Global: Cancer/Tumor Profiling (Other Cancer Types) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 21: Global: Cancer/Tumor Profiling (Next-Generation Sequencing-NGS) Market: Sales Value (in Million USD), 2019 & 2024
Figure 22: Global: Cancer/Tumor Profiling (Next-Generation Sequencing-NGS) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 23: Global: Cancer/Tumor Profiling (Polymerase Chain Reaction-PCR) Market: Sales Value (in Million USD), 2019 & 2024
Figure 24: Global: Cancer/Tumor Profiling (Polymerase Chain Reaction-PCR) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 25: Global: Cancer/Tumor Profiling (Immunohistochemistry-IHC) Market: Sales Value (in Million USD), 2019 & 2024
Figure 26: Global: Cancer/Tumor Profiling (Immunohistochemistry-IHC) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 27: Global: Cancer/Tumor Profiling (In-Situ Hybridization-ISH) Market: Sales Value (in Million USD), 2019 & 2024
Figure 28: Global: Cancer/Tumor Profiling (In-Situ Hybridization-ISH) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 29: Global: Cancer/Tumor Profiling (Microarray) Market: Sales Value (in Million USD), 2019 & 2024
Figure 30: Global: Cancer/Tumor Profiling (Microarray) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 31: Global: Cancer/Tumor Profiling (Other Technologies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 32: Global: Cancer/Tumor Profiling (Other Technologies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 33: Global: Cancer/Tumor Profiling (Genomics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 34: Global: Cancer/Tumor Profiling (Genomics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 35: Global: Cancer/Tumor Profiling (Proteomics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 36: Global: Cancer/Tumor Profiling (Proteomics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 37: Global: Cancer/Tumor Profiling (Epigenetics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 38: Global: Cancer/Tumor Profiling (Epigenetics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 39: Global: Cancer/Tumor Profiling (Metabolomics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 40: Global: Cancer/Tumor Profiling (Metabolomics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 41: Global: Cancer/Tumor Profiling (Personalized Medicine) Market: Sales Value (in Million USD), 2019 & 2024
Figure 42: Global: Cancer/Tumor Profiling (Personalized Medicine) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 43: Global: Cancer/Tumor Profiling (Diagnostics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 44: Global: Cancer/Tumor Profiling (Diagnostics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 45: Global: Cancer/Tumor Profiling (Biomarker Discovery) Market: Sales Value (in Million USD), 2019 & 2024
Figure 46: Global: Cancer/Tumor Profiling (Biomarker Discovery) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 47: Global: Cancer/Tumor Profiling (Prognostics) Market: Sales Value (in Million USD), 2019 & 2024
Figure 48: Global: Cancer/Tumor Profiling (Prognostics) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 49: Global: Cancer/Tumor Profiling (Other Applications) Market: Sales Value (in Million USD), 2019 & 2024
Figure 50: Global: Cancer/Tumor Profiling (Other Applications) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 51: North America: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 52: North America: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 53: United States: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 54: United States: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 55: Canada: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 56: Canada: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 57: Asia-Pacific: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 58: Asia-Pacific: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 59: China: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 60: China: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 61: Japan: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 62: Japan: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 63: India: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 64: India: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 65: South Korea: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 66: South Korea: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 67: Australia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 68: Australia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 69: Indonesia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 70: Indonesia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 71: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 72: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 73: Europe: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 74: Europe: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 75: Germany: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 76: Germany: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 77: France: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 78: France: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: United Kingdom: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 80: United Kingdom: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 81: Italy: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 82: Italy: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 83: Spain: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 84: Spain: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 85: Russia: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 86: Russia: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 87: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 88: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 89: Latin America: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 90: Latin America: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 91: Brazil: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 92: Brazil: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 93: Mexico: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 94: Mexico: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 95: Others: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 96: Others: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 97: Middle East and Africa: Cancer/Tumor Profiling Market: Sales Value (in Million USD), 2019 & 2024
Figure 98: Middle East and Africa: Cancer/Tumor Profiling Market: Breakup by Country (in %), 2024
Figure 99: Middle East and Africa: Cancer/Tumor Profiling Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 100: Global: Cancer/Tumor Profiling Industry: SWOT Analysis
Figure 101: Global: Cancer/Tumor Profiling Industry: Value Chain Analysis
Figure 102: Global: Cancer/Tumor Profiling Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Cancer/Tumor Profiling Market: Key Industry Highlights, 2024 and 2033
Table 2: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Cancer Type (in Million USD), 2025-2033
Table 3: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Technology (in Million USD), 2025-2033
Table 4: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Technique (in Million USD), 2025-2033
Table 5: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Application (in Million USD), 2025-2033
Table 6: Global: Cancer/Tumor Profiling Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 7: Global: Cancer/Tumor Profiling Market: Competitive Structure
Table 8: Global: Cancer/Tumor Profiling Market: Key Players

Product Code: SR112025A5231

The global cancer/tumor profiling market size was valued at USD 12.47 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 26.29 Billion by 2033, exhibiting a CAGR of 8.21% during 2025-2033. North America currently dominates the market, holding a significant market share of over 42.8% in 2024. The market is experiencing significant growth driven by advancements in precision medicine, rising cancer prevalence and increasing adoption of personalized treatment approaches. Growing demand for biomarker-based diagnostics coupled with technological innovations in genomic and proteomic profiling, further fuels market expansion.

The cancer/tumor profiling market is driven by advancements in genomic and proteomic technologies enabling precise molecular diagnostics. Increasing prevalence of cancer globally coupled with the rising demand for personalized medicine accelerates cancer/tumor profiling market growth. For instance, in December 2024, Aster DM Healthcare announced the launch three initiatives Precision Oncology Clinics, the Aster Cancer Grid and Onco Collect during the Aster Cancer Conclave. These programs aim to enhance personalized data-driven cancer care through genomic approaches promote collaborative research and improve patient outcomes positioning India as a leader in innovative cancer treatment. Government funding and private investments in oncology research also play a pivotal role. Next-generation sequencing (NGS) and biomarker discovery are becoming increasingly adopted for early detection and targeted therapies while technological innovations in liquid biopsy improve profiling accuracy and enhance market expansion.

The United States cancer/tumor profiling market is driven by the high prevalence of cancer and the increasing demand for personalized medicine. According to the data published by the National Library of Medicine, in 2024 an estimated 2,001,140 new cancer cases and 611,720 deaths are projected in the U.S. Advancements in genomic and proteomic technologies such as next-generation sequencing (NGS) enhance the accuracy of tumor profiling. Substantial government funding and investments in oncology research further support market growth.

Cancer/Tumor Profiling Market Trends:

Rising Prevalence of Cancer

The increasing prevalence of cancer in the world has provided a considerable thrust to this growth. Cancer incidence is at its peak, as with an ever-growing focus on exact and specific diagnosis solutions towards the betterment of patient results, the necessity of advanced methods for tumor profiling keeps increasing every year. The American Cancer Society reported that nearly 20 million cases of cancer were diagnosed worldwide in 2022, resulting in 9.7 million deaths due to the disease. This concerning trend highlights the urgent need for better diagnostic and treatment options. Additionally, it is projected that the number of cancer cases could rise to 35 million by 2050, driven by factors such as an aging population, lifestyle changes, and environmental impacts. These statistics point out how tumor profiling plays an increasingly pivotal role in serving the needs for tailored therapies and improved survival in cancer care.

Advancements in Genomics and Precision Medicine

Advances in genomic technologies, including NGS and proteomics, have revolutionized the study of cancer and treatment processes. It is because of this that growth in the tumor profiling market has taken a massive pace. With such advanced technologies, comprehensive tumor profiling is achieved that leads to developing personalized therapies on the basis of the genetic make-up of each individual patient. The results of treatment are improving, and there is a greater emphasis on providing precise care for cancer patients. Reports indicate that global investments in cancer medicine totaled around USD 196 billion in 2022, with an average growth rate of approximately 12% over the last five years. The growing requirement for innovative diagnostics and therapeutic applications has led to an increased utilization of advanced genomic technologies for profiling tumors. These developments are creating positive cancer/tumor profiling market outlook by changing the oncology landscape, opening the way for more effective and targeted cancer treatments.

Government and Research Funding

Investment and funding for cancer and precision medicine are growing largely and thus boosting tumor profiling. The governments, pharmaceutical companies, and other research organizations collaborate on the development of more advanced profiling solutions, which speed up the advancement in early diagnosis and treatment methods for cancer. The UK Government has committed to increasing its total investment in research and development (R&D) to 2.4% of GDP by the year 2027, as reported by Cancer Research UK. Such programs underscore the growing focus on innovation in cancer diagnostics and treatments, which drives cancer/tumor profiling market demand. These investments do not only make precision medicine more accessible but also fuel breakthrough innovations in the personalized treatment of cancer, thereby fueling the market growth.

Cancer/Tumor Profiling Industry Segmentation:

Analysis by Cancer Type:

Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Melanoma Cancer
Others

Breast cancer leads the cancer/tumor profiling market due to its high global prevalence and the increasing adoption of personalized medicine in oncology. Advanced profiling techniques such as next-generation sequencing (NGS) and immunohistochemistry (IHC) play a crucial role in identifying biomarkers for targeted therapies improving patient outcomes. The growing focus on early detection coupled with the rising availability of breast cancer-specific diagnostic tests and therapies drives market growth. Continuous research efforts and clinical trials further strengthen breast cancer's leadership in this sector.

Analysis by Technology:

Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Immunohistochemistry (IHC)
In-Situ Hybridization (ISH)
Microarray
Others

NGS is one of the most prominent technologies in the cancer/tumor profiling market which enables the comprehensive genomic analysis for identifying cancer mutations and biomarkers. Its high-throughput capability and precision facilitate personalized treatments and diagnostics. Increasing adoption of NGS in clinical oncology and its application in targeted therapies and companion diagnostics significantly drive its demand in cancer profiling research.

PCR is highly used in cancer/tumor profiling because of its high sensitivity and specificity in detecting genetic mutations and alterations. It is also very important in the analysis of minimal DNA samples which makes it ideal for early cancer detection. The advancements in real-time and digital PCR further enhance its utility which has fostered its growth as a critical technology in oncology diagnostics.

IHC is one of the core technologies used to identify the tumor's specific protein and biomarkers profiles. This method's usefulness in finding hormone receptors status for example in breast cancer is confirmed by determining the expression of HER2 in cancer. IHC supports personalized treatment approaches through the selection of targeted therapies by a clinician based on biomarker expression patterns.

ISH technology is also used for cancer profiling. This technology can accurately visualize genetic abnormalities directly in tissue samples. It is highly efficient in detecting gene amplifications, translocations and deletions. Applications include the identification of HER2/neu in breast cancer and other chromosomal aberrations. Its use is continuously propelled by the rising demand for accurate molecular diagnostics.

Microarray technology supports cancer profiling by analyzing gene expression patterns and identifying biomarkers associated with tumor development. It enables large-scale screening of genetic data providing insights into cancer classification and progression. The utility of the technology in discovering therapeutic targets and stratifying patients for clinical trials makes it a valuable tool in oncology research and diagnostics.

Analysis by Technique:

Genomics
Proteomics
Epigenetics
Metabolomics

Genomics leads the market with around 39.8% of cancer/tumor profiling market share in 2024. Genomics is the largest technique in the cancer/tumor profiling market because it plays a central role in understanding the genetic basis of cancer. Genomic profiling allows for the identification of mutations, gene expression patterns and biomarkers critical for personalized oncology. Technologies such as next-generation sequencing (NGS) and microarrays drive this segment by offering high-throughput and precise analyses. The rise in targeted therapies advancements in companion diagnostics and the increasing adoption of genomics within clinical oncology heighten its presence further while promoting successful treatment outcomes and new areas for research.

Analysis by Application:

Personalized Medicine
Diagnostics
Biomarker Discovery
Prognostics
Others

The personalized medicine segment is highly important in the cancer/tumor profiling market as it provides for treatment based on an individual's genetic and molecular profile. This improves the effectiveness of therapy while minimizing side effects targeting the specific biomarkers. Increasing precision oncology adoption and advancement in tumor profiling techniques propel this segment's growth significantly which also enhances patient outcomes.

The market is dominated by the diagnostics segment mainly because of the accurate type and stage of cancer identification via advanced tumour profiling techniques. Technologies such as PCR, NGS and IHC enable early diagnosis and improved decision-making in treatment plans. The demand for early screening of cancer and non-invasive diagnostic solutions is therefore driving further expansion in this critical application area.

Biomarker discovery is one of the key applications of cancer profiling focused on identifying molecular markers associated with cancer development and progression. This helps in targeted drug development and companion diagnostics that drive the evolution of precision medicine. Continuous genomics and proteomics research coupled with increased investments in oncology studies propel this segment in the market.

The prognostics segment is used to predict the progression of cancer, survival rate of patients and possible treatment response through tumor profiling. It supports the planning of treatment on an individual basis by analyzing genetic mutations and biomarkers. Rising awareness of the benefits of prognostic tools and advancements in molecular diagnostics contribute to the growing adoption of prognostic applications in the cancer/tumor profiling market.

Regional Analysis:

North America
- United States
- Canada
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

In 2024, North America accounted for the largest market share of over 42.8%. North America dominates the cancer/tumor profiling market with the region witnessing an advanced healthcare infrastructure, high adoption of precision medicine and substantial investments in oncology research. The region benefits from the widespread availability of advanced diagnostic technologies such as NGS and PCR along with a strong presence of key market players. Rising cancer prevalence and government initiatives to support cancer screening and biomarker research further propel market growth. With higher clinical trials and research collaborations among research institutes North America leads this market.

Key Regional Takeaways:

United States Cancer/Tumor Profiling Market Analysis

In 2024, the United States captured 88.9% of revenue in the North American market. The American Cancer Society anticipates more than 1.9 million new cancer cases in the U.S. for 2024. It's estimated that 1 in 23 men and 1 in 24 women will be diagnosed with colorectal cancer at some point in their lives. Current projections for 2023 suggest that there will be 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer in the U.S. With this trend in cancer, growing need is being seen to develop diagnostic and prognostic tools at more advanced levels such as tumor profiling. Tumor profiling provides more informative molecular data which helps identify mutations, biomarkers, and targets of therapy. As healthcare systems look to the earlier diagnosis and tailoring of therapy to improve outcomes in patients there will be immense opportunities for the growth of the cancer/tumor profiling market.

Europe Cancer/Tumor Profiling Market Analysis

The Europe cancer/tumor profiling market is experiencing significant growth driven by the rising burden of cancer particularly due to an ageing population. From 2010 to 2020, the European population living with cancer saw an annual increase of 3.5% leading to an overall rise of 41% according to the EU Science Hub. With the aging population the prevalence of cancer is anticipated to grow which will increase the need for advanced diagnostic technologies such as tumor profiling. These technologies such as next-generation sequencing (NGS) and liquid biopsy enable early cancer detection and personalized treatment strategies improving patient outcomes. With an increased focus on precision medicine and the growing recognition of the benefits of early and accurate cancer detection Europe is seeing an uptick in the adoption of tumor profiling solutions. Additionally, the region's strong healthcare infrastructure and government support for cancer research are expected to continue driving market expansion in the coming years.

Asia Pacific Cancer/Tumor Profiling Market Analysis

The Asia Pacific region experiences a considerable burden from cancer with the five most prevalent types being lung cancer (1,315,136 new cases), breast cancer (1,026,171 cases), colorectal cancer (1,009,400 cases), stomach cancer (819,944 cases) and liver cancer (656,992 cases) as reported by NIH data. This rising incidence is fueling the demand for advanced cancer diagnostics including tumor profiling technologies like next-generation sequencing (NGS) and liquid biopsy. As healthcare infrastructure improves across countries like China, India and Japan there is a strong push for precision medicine and personalized therapies. These innovations are driving the adoption of tumor profiling tools to enhance early detection, guide treatment decisions and improve patient outcomes. Government initiatives, increased healthcare spending and strategic partnerships with global biotech and pharmaceutical firms are accelerating the adoption of these technologies in the region. The Asia Pacific cancer/tumor profiling market is poised for significant growth driven by the need for more effective tailored cancer care solutions.

Latin America Cancer/Tumor Profiling Market Analysis

As cited by the ESMO 2022 report Latin America presents a significant burden of cancer. An estimated 1.5 million new cases and 700,000 deaths are reported yearly. The cancer incidence and mortality rates in this region stand at 186.5 and 86.6 per 100,000, indicating a pressing requirement for advanced diagnostic solutions. Cancer has recently been a new tool for tackling cancer by way of personalising the treatment processes to suit every patient's specific genetic makeup. This, besides enhancing patient results, has managed to tackle cancer mortality rates across the region. Governments in Latin America are pouring more investments in healthcare infrastructure; the emphasis lies on early detection and precision medicine to curb rising cancer burdens. The innovation in diagnostic techniques is driven by collaborations between regional healthcare providers and global biotechnology firms, increasing access to next-generation sequencing and other tumor profiling technologies. Such efforts are expected to fuel the growth of the tumor profiling market, bringing hope for better cancer management across the region.

Middle East and Africa Cancer/Tumor Profiling Market Analysis

The Middle East and Africa (MEA) region is undergoing a significant change in the increasing number of cancer cases. Ingestion of lifestyle changes, aging populations, and a burgeoning environmental risk factor are widespread. Cancer incidence is projected to increase 1.8-fold by 2030 in Arab countries, according to the NIH, further necessitating advanced diagnostic and treatment solutions. The demand for cancer/tumor profiling is accelerating as healthcare systems in the region focus on early detection and personalized treatment approaches to improve patient outcomes. Governments and private organizations are increasingly investing in healthcare infrastructure, research initiatives, and collaborations with global biotechnology companies to bring state-of-the-art technologies, such as next-generation sequencing (NGS) and liquid biopsy solutions, to the region. It can be attributed to the presence of initiatives like UAE National Cancer Registry and healthcare targets set in Saudi Arabia through its Vision 2030, leading to an advance in cancer profiling. This, too, will foster growth for the MEA market on cancer/tumor profiling.

Competitive Landscape:

The cancer/tumor profiling market is highly competitive with key players focusing on innovation, strategic partnerships and product development to strengthen their market presence. Leading companies are driving advancements in genomic and molecular diagnostics. These firms invest heavily in research and development to introduce advanced profiling technologies such as NGS and biomarker-based diagnostics. Additionally, collaborations between biotechnology companies, research institutions and healthcare providers are fueling market expansion. Emerging players are also leveraging technological advancements and targeting niche segments to gain a competitive edge further intensifying the market's dynamic landscape.

The report provides a comprehensive analysis of the competitive landscape in the cancer tumor profiling market with detailed profiles of all major companies, including:

Abbott Laboratories
Becton Dickinson and Company
Caris Life Sciences
Exact Sciences Corporation
F. Hoffmann-La Roche Ltd
Hologic Inc.
HTG Molecular Diagnostics Inc.
Illumina Inc.
Laboratory Corporation of America Holdings
NeoGenomics Laboratories
Qiagen N.V.
Siemens AG
Sysmex Corporation

Latest News and Developments:

October 2024: Illumina announced its partnership with AstraZeneca to develop innovative next-generation sequencing (NGS)-based companion diagnostics, strengthening its capabilities in oncology-related solutions.
September 2024: Thermo Fisher launched the Oncomine Comprehensive Assay Plus, a targeted NGS tool designed to detect essential mutations in solid tumors, demonstrating its dedication to improving diagnostic options in cancer genomics.
November 2023: Illumina unveiled the latest version of its liquid biopsy assay for genomic profiling, the TruSight Oncology 500 ctDNA v2. This assay is intended to deliver thorough genomic insights from blood samples, especially useful for patients when tissue testing is not feasible.
May 2023: Pfizer announced its partnership with Thermo Fisher Scientific in a strategic collaboration aimed at increasing the availability of NGS-based testing for lung and breast cancer patients across more than 30 countries.

Key Questions Answered in This Report

1.How big is the cancer/tumor profiling market?
2.What is the future outlook of cancer/tumor profiling market?
3.What are the key factors driving the cancer/tumor profiling market?
4.Which region accounts for the largest cancer/tumor profiling market share?
5.Which are the leading companies in the global cancer/tumor profiling market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Cancer/Tumor Profiling Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Cancer Type

6.1 Breast Cancer
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Lung Cancer
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Colorectal Cancer
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Prostate Cancer
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Melanoma Cancer
- 6.5.1 Market Trends
- 6.5.2 Market Forecast
6.6 Others
- 6.6.1 Market Trends
- 6.6.2 Market Forecast

7 Market Breakup by Technology

7.1 Next-Generation Sequencing (NGS)
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Polymerase Chain Reaction (PCR)
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Immunohistochemistry (IHC)
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 In-Situ Hybridization (ISH)
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Microarray
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast

8 Market Breakup by Technique

8.1 Genomics
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Proteomics
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Epigenetics
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
8.4 Metabolomics
- 8.4.1 Market Trends
- 8.4.2 Market Forecast

9 Market Breakup by Application

9.1 Personalized Medicine
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Diagnostics
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Biomarker Discovery
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
9.4 Prognostics
- 9.4.1 Market Trends
- 9.4.2 Market Forecast
9.5 Others
- 9.5.1 Market Trends
- 9.5.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia-Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Abbott Laboratories
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Becton Dickinson and Company
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Caris Life Sciences
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
- 15.3.4 Exact Sciences Corporation
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 F. Hoffmann-La Roche Ltd
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 Financials
- 15.3.6 Hologic Inc.
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 HTG Molecular Diagnostics Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
- 15.3.8 Illumina Inc.
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Laboratory Corporation of America Holdings
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 NeoGenomics Laboratories
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
- 15.3.11 Qiagen N.V.
  - 15.3.11.1 Company Overview
  - 15.3.11.2 Product Portfolio
  - 15.3.11.3 Financials
  - 15.3.11.4 SWOT Analysis
- 15.3.12 Siemens AG
  - 15.3.12.1 Company Overview
  - 15.3.12.2 Product Portfolio
  - 15.3.12.3 Financials
  - 15.3.12.4 SWOT Analysis
- 15.3.13 Sysmex Corporation
  - 15.3.13.1 Company Overview
  - 15.3.13.2 Product Portfolio
  - 15.3.13.3 Financials
  - 15.3.13.4 SWOT Analysis

がん/腫瘍プロファイリング市場レポート、規模、シェア、動向、予測：がんタイプ、技術、技法、用途、地域別、2025年～2033年

Cancer/Tumor Profiling Market Report Size, Share, Trends, and Forecast by Cancer Type, Technology, Technique, Application, and Region, 2025-2033

がん/腫瘍プロファイリング市場動向：

目次

第1章 序文

第2章 調査範囲と調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

第5章 世界のがん/腫瘍プロファイリング市場

第6章 市場内訳：がんタイプ別

第7章 市場内訳：技術別

第8章 市場内訳：技法別

第9章 市場内訳：用途別

第10章 市場内訳：地域別

第11章 SWOT分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 価格分析

第15章 競合情勢